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Abstract 
Deletions spanning the STS (steroid sulfatase) gene at Xp22.31 are associated with X-linked ichthyosis, 
corneal opacities, testicular maldescent, cardiac arrhythmia, and higher rates of developmental and mood 
disorders/traits, possibly related to the smaller volume of some basal ganglia structures. The consequences 
of duplication of the same genomic region have not been systematically assessed in large or adult samples, 
although evidence from case reports/series has indicated high rates of developmental phenotypes. We 
compared multiple measures of physical and mental health, cognition and neuroanatomy in male (n=414) 
and female (n=938) carriers of 0.8-2.5Mb duplications spanning STS, and non-carrier male (n=192,826) and 
female (n=227,235) controls from the UK Biobank (recruited aged 40-69 from the UK general population). 
Clinical and self-reported diagnoses indicated a higher prevalence of inguinal hernia and mania/bipolar 
disorder respectively in male duplication carriers, and a higher prevalence of gastro-oesophageal reflux 
disease and blistering/desquamating skin disorder respectively in female duplication carriers; duplication 
carriers also exhibited reductions in several depression-related measures, and greater happiness. Cognitive 
function and academic achievement did not differ between comparison groups. Neuroanatomical analysis 
suggested greater lateral ventricle and putamen volume in duplication carriers. In conclusion, Xp22.31 
duplications appear largely benign, but could slightly increase the likelihood of specific phenotypes 
(although results were only nominally-significant). In contrast to deletions, duplications might protect 
against depressive symptoms, possibly via higher STS expression/activity (resulting in elevated endogenous 
free steroid levels), and through contributing towards an enlarged putamen volume. These results should 
enable better genetic counselling of individuals with Xp22.31 microduplications.  
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Introduction 
The X-linked STS gene encodes the enzyme steroid sulfatase which catalyses the desulfation of sulfated 
steroids (e.g. dehydroepiandrosterone sulfate, DHEAS) to their free steroid counterparts; these may 
subsequently act as precursors for a variety of androgens and oestrogens (1). Genetic deletions at Xp22.31 
encompassing STS are associated with the rare skin condition X-linked ichthyosis (XLI, OMIM: 308100)(2). 
XLI predominantly affects males, and is associated with a number of conditions including cryptorchidism 
and benign corneal opacities; some female deletion carriers also have corneal opacities and can exhibit 
prolonged/delayed labour during childbirth as a consequence of STS deficiency in the fetal portion of the 
placenta (2). We have recently shown that males with deletions spanning STS are at significantly increased 
risk of atrial fibrillation/flutter compared to male non-carriers (3). Occasional comorbidities with XLI can 
include focal epilepsy (4), pyloric hypertrophy, congenital defect of the abdominal wall, acute lymphoblastic 
leukaemia, bilateral periventricular nodular heterotopia and end-stage renal failure (2). Deletions around STS 
are also associated with substantially elevated rates of developmental disorders (notably autism and 
inattentive Attention Deficit Hyperactivity Disorder (ADHD))(5-7), and with elevated rates of associated 
cognitive, motor and mood symptoms (3,8,9); these psychological features may stem from subcortical brain 
structure differences, notably a reduction in the size of some regions of the basal ganglia (3). Rare, larger 
genetic deletions around STS are associated with a number of more severe neurological conditions including 
Kallman, Rud, and Conradi syndromes (2). 
Whilst the phenotypes associated with XLI-associated deletions are reasonably well-characterised, 
the phenotypes associated with the reciprocal duplications have yet to be investigated systematically in large 
or adult samples. Case series/studies documenting predominantly young, clinically-ascertained, individuals 
with Xp22.31 duplications report a number of neurological features including intellectual 
disability/cognitive impairment (40%), autism or autistic behaviours (10-20%), global developmental delay 
(10%), delayed speech and language (10%) and seizures (10%), as well as other less common clinical 
manifestations including microcephaly (5-10%), muscular hypotonia (5-10%) and clinodactyly or shortness 
of the fifth finger (5%)(10-20, and Supplementary Table 1). Whether the Xp22.31 duplication is 
pathogenic (particularly with regard to its role in brain function and head/facial dysmorphism), or whether it 
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is benign but tends to occur in combination with other pathogenic mechanisms, has been a matter for debate 
(21-23).  
In this study, we exploited the power of the genotyped and extensively-characterised large UK 
Biobank sample comprising adults recruited from the general population of the UK (24) to compare a wide 
range of physical and psychiatric illnesses (and treatments), cognitive function, and subcortical brain 
structure, in male and female Xp22.31 duplication carriers to that of sex-matched control subjects not 
carrying the variant of interest. Triangulation of multiple objective and self-report Biobank measures is 
likely to provide comprehensive and accurate information about an individual’s phenotype, including their 
mental health (25). A priori, we considered the possibilities that duplication carriers within our sample may 
exhibit similar, contrasting, and/or distinct phenotypes to deletion carriers, or that duplications carriers may 
exhibit few, if any, phenotypic differences from non-carrier controls.      
 
Results 
Identification and characterisation of duplication cases 
We identified 414 male and 938 female duplication carriers, alongside 192,826 male and 227,235 female 
non-carriers, giving prevalence rates of  1/470 (0.21%) in males and  1/240 (0.41%) in females. The mean 
duplication size was 1.60±0.46Mb from ChrX:6,477,469-8,080,874 encompassing the HDHD1/PUDP 
(OMIM:306480), STS (OMIM:300747), VCX (OMIM:300229) and PNPLA4 (OMIM:300102) genes and the 
MIR4767 microRNA. 
ICD-10 diagnoses 
We identified ICD-10 unique descriptive codes that were the most common in duplication carriers (present 
in at least 1 in 40 (>2.5%) carriers), and that were also recorded in a significant proportion (>1.5%) of 
individuals in the overall male and female samples; these selection criteria, analogous to those used in our 
previous Xp22.31 deletion study (3), were designed to detect robust between-group effects. 13 ICD-10 
codes met these criteria in the male sample (Supplementary Table 2). Of these, just one ‘Unilateral or 
unspecified inguinal hernia, without obstruction or gangrene’ was nominally-significantly more commonly 
observed in male duplication carriers than in male non-carrier controls (9.4% vs. 6.8%, OR: 1.42 (95% CI: 
1.02-1.97), 2[1]=3.95, p=0.047); this result did not remain significant after correction for multiple testing. 
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We have previously shown that male deletion carriers in the UK Biobank exhibit significantly increased 
prevalence of ‘atrial fibrillation/flutter’ and ‘skin of other and unspecified parts of face’ relative to male 
non-carrier controls; analysis of these two phenotypes in male duplication carriers revealed no significant 
difference from non-carrier controls (atrial fibrillation: 2.4% vs. 2.7% respectively, OR: 0.88 (95% CI: 0.47-
1.66), 2[1]=0.06, p=0.82; Skin: 1.7% vs. 1.5% respectively, OR: 1.12 (95% CI: 0.53-2.37), 2[1]=0.009, 
p=0.92). 
We identified 16 ICD-10 unique descriptive codes that met the aforementioned selection criteria in 
the female sample (Supplementary Table 3). Of these, only one, ‘Gastro-oesophageal reflux disease 
(GORD) without oesophagitis’ was significantly more common in duplication carriers than in non-carrier 
controls (2.7% vs. 1.6%, OR: 1.69 (95% CI: 1.13-2.51), 2[1]=4.88, p=0.027); again, this finding did not 
survive correction for multiple testing.    
The number of ‘inguinal hernia’ diagnoses did not differ significantly between female duplication 
carriers and female non-carrier controls (0.6% vs. 0.4% respectively, OR: 1.62 (95%CI: 0.72-3.63), p=0.20), 
nor did the number of ‘GORD without oesophagitis’ diagnoses differ between male duplication carriers and 
male non-carrier controls (1.0% vs. 1.2% respectively, OR: 0.82 (95%CI: 0.31-2.19), p=1.00).    
Clinical diagnosis rates of developmental and mood/anxiety disorders were not significantly different 
between male and female duplication and sex-matched control cohorts (Supplementary Tables 4 and 5), 
although baseline diagnosis rates were low across all groups. 
Self-reported non-cancer illnesses 
We analysed a number of medical and psychiatric/neurological self-reported diagnoses across all groups; the 
phenotypes we assessed were indicated by the ICD-10 data above, were related to tissues with high STS 
expression, or were potentially sensitive to dosage of the region of interest as indicated by previous deletion 
carrier data.  
No physical health conditions we assessed were self-reported at significantly higher rates in male 
duplication carriers compared to male non-carrier controls, although rates of ‘inguinal hernia’ and ‘gastro-
oesophageal reflux’ tended to be higher in the former than the latter group (1.9% vs. 0.9%, p=0.065; 6.0% 
vs. 4.7%, 2[1]=1.44, p=0.20 respectively) (Supplementary Table 6). Only one self-reported psychiatric 
condition (‘mania/bipolar disorder’) differed in prevalence between male groups with higher rates in the 
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duplication group compared to the control group (1.0% vs. 0.3%, p=0.026); this finding did not survive 
correction for multiple testing (corrected p-value>0.99)(Supplementary Table 6). 
Only one of the physical health conditions we assessed (‘blistering/desquamating skin disorder’) was 
significantly more commonly self-reported in female duplication carriers compared to female non-carrier 
controls (0.5% vs. 0.1%, p=0.013), although this result did not withstand multiple testing correction 
(corrected p=0.69); the self-reported prevalence of ‘inguinal hernia’ and ‘gastro-oesophageal reflux’ was 
similar in female duplication carriers and in female controls (0.1% vs. 0.1%, p=0.51; 4.1% vs. 4.4%, 
2[1]=0.20, p=0.63) (Supplementary Table 7). No psychiatric/neurological conditions we assessed differed 
in self-reported prevalence between female duplication and control groups (Supplementary Table 7). 
Mental Health Questionnaire (MHQ) 
The MHQ was completed by a total of 129 male duplication carriers, 59,418 male controls, 269 female 
duplication carriers and 76,265 female controls. Neither male nor female duplication carriers completing the 
MHQ self-reported differing frequencies of mental distress or mental health diagnoses relative to sex-
matched controls (Table 1).  
Male duplication carriers differed from sex-matched controls most frequently with respect to 
depression-related symptoms and treatments (Supplementary Table 8). Specifically, compared to controls, 
duplication carriers reported a lower prevalence of ‘prolonged feelings of sadness or depression’ (34% vs. 
44%, OR: 0.66 (95%CI: 0.46-0.96), 2[1]=4.51, p=0.034), reduced ‘recent feelings of tiredness or low 
energy’ (p=0.022, d<0.02), lower ‘number of lifetime depressed periods’ (p=0.049, d<0.03) and elevated 
levels of ‘general happiness’ (p=0.019, d<0.02); those male duplication carriers who did experience 
depressive episodes, less frequently experienced ‘feelings of worthlessness during the worst period of 
depression’ (32% vs. 48%, OR: 0.50 (95%CI:0.26-0.94), 2[1]=4.16, p=0.041) and were more likely to 
engage in talking therapies (38% vs. 15%, OR:3.36 (95%CI:1.59-7.11), 2[1]=4.16, p=0.041). These effects 
in the male duplication carrier group are unlikely to be a consequence of lower exposure to traumatic events, 
in that this group generally reported experiencing similar levels of adverse events to the control group, and 
actually experienced a diagnosis of a life-threatening illness significantly more commonly (p=0.049, 
d<0.015)(Supplementary Table 8). Male duplication carriers did not self-report differently to non-carrier 
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controls with respect to manic/bipolar disorder symptoms, anxiety-related symptoms, addictive behaviours, 
alcohol or cannabis use, or unusual and psychotic experiences (Supplementary Table 8). 
Female duplication carriers also differed from sex-matched controls most consistently with respect to 
depression-related symptoms and treatments (Supplementary Table 9). Fewer duplication carriers reported 
sleep changes during depressive episodes (76% vs. 83%, OR:0.62 (95%CI:0.42-0.91), 2[1]=5.50, p=0.019) 
and fewer reported ‘difficulty concentrating during their worst depressive episode’ (72% vs. 81%, OR:0.61 
(95%CI: 0.42-0.87), 2[1]=6.89, p=0.009). Female duplication carriers were also less likely to have taken 
prescribed substances for depression than female controls (22% vs. 30%, OR:0.65 (95%CI:0.49-0.87), 
2[1]=7.96, p=0.005), but more likely to have taken alcohol/drugs to manage depressive symptoms (10% vs. 
7%, OR:1.62 (95%CI:1.09-2.40), 2[1]=5.32, p=0.021). A smaller proportion of female duplication carriers 
than controls who experienced anxiety self-reported being easily tired during their worst episode (65% vs. 
76%, OR: 0.61 (95%CI:0.39-0.96), 2[1]=4.02, p=0.045), but a significantly larger proportion of duplication 
carriers reported using alcohol/drugs to manage anxiety symptoms (8% vs. 5%, OR:1.63 (95%CI:1.05-2.53), 
2[1]=4.33, p=0.037). Duplications in female participants were not associated with manic/bipolar disorder 
symptoms, addictive behaviours, alcohol or cannabis use, unusual and psychotic experiences, experiencing 
traumatic events, or happiness/subjective wellbeing (Supplementary Table 9).   
Medications 
We compared prescription rates of medications for gastric reflux, blistering/desquamating disorders and 
psychiatric conditions indicated above in male and female duplication carriers and controls. There was a 
trend for male duplication carriers to be prescribed proton pump inhibitors more frequently than male 
controls (11.1% vs. 8.3%, OR:1.38 (95%CI:1.01-1.87), 2[1]=3.85, p=0.050, corrected p=0.40), but there 
was no between-group difference for antacids or H2 receptor antagonists; prescription rates of psychiatric 
medications were similar between male duplication carriers and male controls (Supplementary Table 10). 
Female duplication carriers and controls were prescribed all of the aforementioned medications at equivalent 
rates (Supplementary Table 11).   
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Academic qualifications and cognitive function 
Male and female duplication carriers did not differ significantly from their sex-matched controls in terms of 
their highest academic qualification (Table 2). Regression analysis controlling for age at testing indicated 
that male duplication carriers performed equivalently to male controls across all of the cognitive measures 
we assessed (Table 3). Female duplication carriers performed similarly to female controls on all measures 
apart from the number of correct substitutions within the Symbol Digit Substitution task (an index of 
complex processing), where they performed slightly worse (B=-0.254±0.108, β=-0.019, p=0.019); this result 
did not remain significant after correction for multiple testing (Table 3).  
Intra-cranial volume and subcortical neuroanatomy 
As both microcephaly and macrocephaly have been reported in duplication carriers, we initially tested 
whether intra-cranial volume (a surrogate measure of skull size) was associated with duplication carrier 
status after adjusting for age at scanning, handedness and scanning centre; this did not appear to be the case 
for either male (B=10.753.4, =0.004, p=0.84) or female (B=15.527.7, =0.010, p=0.58) participants. 
Regression analysis adjusting for age at scanning, intra-cranial volume, handedness and scanning centre, 
indicated a nominally-significantly enlarged left lateral ventricle size in male duplication carriers compared 
to controls (B=4.582.20, =0.036, p=0.038), a result which did not survive correction for multiple testing; 
however, consistent with this, male duplication carriers exhibited a trend towards enlarged right lateral 
ventricle volumes, and female duplication carriers also exhibited enlarged left and right lateral ventricles on 
average relative to female controls (Table 4). Equivalent regression analysis in females indicated a 
nominally-significantly enlarged left putamen in duplication carriers relative to controls (B=0.310.14, 
=0.037, p=0.033, corrected p=0.53); both left and right putamen volumes were, on average, also higher in 
male duplication carriers than male controls (Table 4).  
 
Discussion 
Here, we have systematically compared the prevalence/magnitude of a wide range of medical and 
neurobehavioural phenotypes in male and female carriers of small Xp22.31 duplications to that in sex-
matched non-carrier controls, using a large adult sample drawn from the UK general population. As male 
and female duplication carriers did not differ from sex-matched controls across the vast majority of the large 
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number of measures we assessed, our data indicate that within this sample (and presumably across a 
substantial proportion of the general population), such variants are generally benign. Previous data from 
clinical case studies/series have indicated that these microduplications are often associated with severe 
neurological and physical phenotypes. To resolve this apparent paradox we argue that in many previously-
described cases the duplication may be an innocent bystander or a risk factor, and that other co-occurring 
genetic (e.g. alternative damaging copy number variants), environmental or stochastic factors acting in 
parallel with it predispose to the more severe phenotypes. Alternatively, it is possible that the duplication is 
pathogenic in a proportion of cases, and that these cases are not ascertained into the UK Biobank; 
individuals with developmental disorders/learning disabilities and other major health issues are under-
represented in this sample (26).  
  The prevalence of Xp22.31 microduplications has been reported as 0.41% in general population 
controls (0.18% in males, and 0.52% in females) (18); the overall rate of 0.32% which we observed, in a 
sample >80 times larger, is of comparable magnitude to this (equivalent to around 200,000 carriers in the 
UK, or >23.5 million carriers worldwide). The 2-3 fold difference in prevalence of the variant between 
females and males in our sample,  and in that of Liu et al. (18), most likely reflects the presence of two X 
chromosomes in females relative to one in males (hence double the opportunity for mutation), but could also 
partially reflect a less severe effect of duplication of this X-inactivation escaping-region in the former sex 
relative to the latter (i.e. a theoretical 50% increase in gene dosage in females compared to a 100% increase 
in gene dosage in males). The 3-4 fold higher prevalence of the duplication relative to the deletion (0.32% 
vs. <0.1%) in the UK Biobank sample likely reflects the comparatively lower pathogenicity of the former 
variant.  
We did identify a small number of phenotypes that differed significantly (p<0.05) in prevalence 
and/or magnitude between groups. However, these comparisons did not survive stringent correction for 
multiple testing, were not statistically significant across both male and female duplication carrier groups, 
were associated with relatively small effect sizes, and were somewhat discrepant across objective and self-
report measures. Hence, the positive results presented here will require replication in alternative large 
samples to test whether they represent true, or false positive, findings. 
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We have previously shown using the UK Biobank sample that deletion of the genomic region 
surrounding STS is associated with an increased rate of depressive-anxiety symptoms (but not diagnoses), 
and a reduction of the volume of sub-regions of the basal ganglia, including the left putamen (3). Our 
present data suggest that duplications of the same region, in both males and females, may impact upon 
similar phenotypes (though in the opposite direction), thus strengthening the evidence for a link between the 
associated genes and mood symptoms; the high expression of STS in the developing human basal ganglia 
(27), together with the enzyme’s regulatory role in neurochemical and steroid hormone-mediated mood 
disorder-related processes (28-30) implicates this gene/protein in particular. Elevated expression of STS in 
duplication carriers is expected to be associated with higher levels of circulating free steroids, including 
dehydroepiandrosterone (DHEA) and allopregnanolone; however, to our knowledge, free steroid levels in 
Xp22.31 duplication carriers have not yet been systematically evaluated. There is some evidence that 
administration of these free steroids may be beneficial in treating aspects of depression (29,31,32). 
Moreover, left putamen volume appears to be consistently smaller in older (33), first episode (34) and 
unmedicated (35) individuals with depression relative to unaffected controls. Hence, we propose that 
microduplications encompassing STS might protect against depressive-anxiety traits developmentally via 
increased free steroid abundance and/or increased putamen volume. The relationship between putamen 
volume and depression-related traits is likely to be complex, in that increased putamen volume has also been 
reported in individuals with psychotic disorder and associated mood symptoms (although this finding may 
be explained by the effects of antipsychotic administration)(36). Interestingly, males carrying duplications 
self-reported being diagnosed with mania/bipolar disorder more often than control males, although rates 
were low across both groups (<1%); there is some evidence that lower concentrations of circulating DHEAS 
(as might be expected in duplication carriers) are correlated with higher mania scores in a sample of patients 
with bipolar disorder (37). Hence, duplications could potentially have dissociable effects on depressive and 
manic traits, acting to reduce the former whilst eliciting the latter. In terms of neuroanatomy, duplication 
carriers also exhibited evidence for enlarged left lateral ventricle volume relative to controls; this finding 
aligns with a previous observation of a widened left lateral ventricle in a fetus possessing an Xp22.31 1.6Mb 
microduplication (21).      
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  Male duplication carriers were significantly more likely to have been diagnosed with inguinal hernia 
than male controls; the prevalence of this condition in our control group (6.8%) was similar to that 
previously observed in adult European males (7.2%)(38). Inguinal hernia has been reported in both Xp22.31 
duplication (Supplementary Table 1) and deletion (39,40) cases, and approximately 20% of deletion cases 
are affected by the related condition of cryptorchidism (2,41). Together, these findings suggest that aberrant 
(either over- or under-) expression of one of more genes in the interval of interest may predispose to 
aberrant inguinal canal anatomy and/or function. Abnormalities in the dosage of STS and consequent 
hormonal changes represent one plausible candidate mechanism underlying this association, although 
altered dosage of other genes within the interval may also be relevant (42); the respective contribution of 
these mechanisms remains to be investigated.  
   Female duplication carriers were more likely to have received a diagnosis of gastro-oesophageal 
reflux disease (without oesophagitis) than female controls. GORD and pyloric stenosis have previously been 
reported in male, but not female,  duplication cases (18 and Supplementary Table 1), and this may be 
consistent with our finding of increased proton pump inhibitor prescription in male duplication carriers. 
GORD is not a condition that is frequently associated with X-linked ichthyosis. Hence, the putative 
relationship between Xp22.31 gene dosage and GORD requires further investigation and clarification. 
Xp22.31 duplication was also associated with a higher self-reported rate of blistering/desquamating disorder 
diagnosis in females but not in males. This result may represent a true finding in that it is consistent with a 
role for genes within this interval (most likely STS) affecting skin morphology in a sex-biased manner, and 
with overexpression eliciting a similar phenotypic effect to under-expression. 
In summary, our data indicate that Xp22.31 duplications are largely benign, with possible small 
protective effects against certain mood symptoms and small risk effects for specific medical conditions. 
Assuming replication of our positive findings, follow-up studies in carrier individuals and in model systems 
should clarify the underlying biological mechanisms. Documenting the full range of phenotypes associated 
with Xp22.31 duplications will be important to facilitate more informed counselling as genetic information 
for a greater proportion of the population becomes available.  
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Materials and Methods 
Participants 
Participants were individuals (40-69yrs) recruited under UK Biobank informed consent procedures between 
2006-2010, for which anonymised genotype/phenotype data were available.  
Copy Number Variant (CNV) calling 
Anonymised genotype data were downloaded as raw (CEL) files from the UK Biobank website, and stored 
and processed as described previously (3). Individuals with duplications of 0.8-2.5Mb spanning STS were 
identified, with calls and coordinates based upon the GRCh37/hg19 genome build. Following QC, CNV data 
were available for a total of 421,413 individuals. CNV data will be transferred to UK Biobank in accordance 
with their policies, and access to the data reported here may be obtained through application to UK Biobank. 
Measures 
Hospital diagnoses according to the International Statistical Classification of Diseases and Related Health 
Problems Revision-10 (ICD-10, >18,000 in total), self-reported non-cancer illnesses, relevant questions 
from the Mental Health Questionnaire (MHQ), and medication history were analysed. Highest levels of 
academic qualification and key performance measures on seven cognitive tasks (transformed and converted 
to z-scores) were analysed as described previously (3). Brain images were acquired using Siemens Skyra 3T 
scanners in UK Biobank’s imaging centres in Cheadle and Newcastle, UK using identical acquisition 
protocols
 
(43); T1-weighted brain images were processed using automated methods implemented in 
FreeSurfer
 
(44) to obtain volumetric estimates for 8 right and left subcortical regions.         
Statistics 
Data were analysed using SPSS v25.0 (IBM Corporation). As male and female duplication phenotypes 
could differ in magnitude and/or nature, two comparisons were performed: male duplication carriers vs. 
male non-carriers, and female duplication carriers vs. female non-carriers. Across the overall sample for 
each cognitive/neuroimaging measure, outlying values >2.2 times the interquartile range below the first 
quartile, or above the third quartile, were excluded. Categorical data were analysed using Chi-squared Test 
(continuity-adjusted for 2x2 analyses)/Fisher Exact Test, with Odds Ratios and 95% confidence intervals 
presented as a measure of effect size. Ordinal/non-normally distributed data were compared using Mann-
Whitney U test, with Cohen’s d presented as a measure of effect size. For cognitive and neuroanatomical 
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analyses hierarchical linear regression with relevant covariates was performed. Data are presented as mean 
values with 95% confidence intervals or as mean values±standard error of the mean. Two-sided P-
values<0.05 were regarded as nominally-significant, with P-values<0.1 after Benjamini-Hochberg 
adjustment
 
regarded as surviving correction for multiple comparisons. 
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Table 1. Frequency of mental distress, help-seeking behaviour and psychiatric illness in male and female 
duplication carriers and sex-matched controls completing the Mental Health Questionnaire 
 
Measure Male control Male duplication Statistical analysis Female control  
Female 
duplication 
Statistical analysis 
Mental distress preventing usual activities (Yes/No) 15229/43273 34/94 2[1] =0.001, p=0.971 29180/46221 100/165 
2
[1] =0.067, p=0.796 
Or ever sought/received help for mental distress (Yes/No) 17695/41526 35/94 2[1] =0.342, p=0.559 35046/40939 115/152 
2
[1] =0.878, p=0.349 
Social anxiety or social phobia (Yes/No) 771/58647 1/128 p>0.99 888/75377 5/264 p=0.250 
Phobia (other than social or agoraphobia) (Yes/No) 586/58832 1/128 p>0.99 1256/75009 2/267 p=0.337 
Panic attacks (Yes/No) 2296/57122 8/121 p=0.166 5189/71076 14/255 2[1] =0.845, p=0.358 
Obsessive compulsive disorder (Yes/No) 336/59082 2/127 p=0.167 507/75758 1/268 p>0.99 
Mania/Bipolar (Yes/No) 309/59109 0/129 p>0.99 371/75894 2/267 p=0.378 
Depression (Yes/No) 9295/50123 16/113 2[1] =0.794, p=0.373 19554/56711 57/212 
2
[1] =2.557, p=0.110 
Bulimia (Yes/No) 18/59400 0/129 p>0.99 388/75877 1/268 p>0.99 
Anxiety, nerves or generalised anxiety disorder (Yes/No) 6369/53049 13/116 2[1] =0.009, p=0.926 12870/63395 35/234 
2
[1] =2.586, p=0.108 
Anorexia (Yes/No) 30/59388 0/129 p>0.99 721/75544 3/266 p=0.745 
Agoraphobia (Yes/No) 119/59299 0/129 p>0.99 413/75852 1/268 p>0.99 
ADHD (Yes/No) 50/59368 1/128 p=0.105 46/76219 0/269 p>0.99 
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Table 2. Highest academic qualification achieved by male and female duplication carriers and sex-matched 
controls 
 
Highest academic 
qualification 
Male control 
(n=182574) 
Male duplication 
(n=396) 
Statistical analysis 
Female control 
(n=212235) 
Female duplication 
(n=871) 
Statistical analysis 
College/University degree 62833 (34%) 140 (35%) 
2[1] =8.117, p=0.149 
67597 (32%) 285 (33%) 
2[1] =2.097, p=0.836 
A/AS Levels 20020 (11%) 34 (9%) 27150 (13%) 116 (13%) 
O Levels/GCSEs 36866 (20%) 73 (18%) 55048 (26%) 208 (24%) 
CSEs 10595 (6%) 34 (9%) 12524 (6%) 50 (6%) 
NVQ/HND/HNC 17905 (10%) 41 (10%) 10069 (5%) 43 (5%) 
None 33959 (19%) 74 (19%) 39847 (19%) 169 (19%) 
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Table 3. Performance on key measures of seven cognitive tasks by male and female duplication carriers and 
sex-matched controls 
 
Cognitive task Control group Duplication group Statistical analysis 
Benjamini-
Hochberg corrected 
p-value 
Male participants 
Pairs Matching Test (total number of errors) -0.048 (-0.038- -0.058) (n=43575) 0.058 (-0.123- 0.239) (n=103) B=0.106±0.102, β=0.005, p=0.297 0.520 
Reaction Time Test -0.087 (-0.078- -0.096) (n=43203) 0.010 (-0.175- 0.195) (n=101) B=0.098±0.093, β=0.005, p=0.295 0.520 
Fluid Intelligence Test (total number of correct answers) 0.162 (0.180- 0.144) (n=13251) -0.030 (-0.397- 0.336) (n=34) 
B=-0.192±0.181, β=-0.009, 
p=0.288 
0.520 
Digit Span Test (maximum number of digits remembered) 0.147 (0.118- 0.176) (n=4242) 0.5031 (-0.040- 1.047) (n=13) B=0.362±0.267, β=0.021, p=0.176 0.520 
Symbol Digit Substitution Test (number of correct 
substitutions) 
-0.010 (-0.026- 0.005) (n=11768) -0.030 (-0.295- 0.234) (n=30) 
B=-0.022±0.158, β=-0.001, 
p=0.887 
0.887 
Trail Making Test A (Time to completion) -0.059 (-0.0760- -0.042) (n=10669) 
-0.011 (-.0.326- -0.305) 
(n=30) 
B=0.052±0.165, β=0.003, p=0.751 0.876 
Trail Making Test B (Time to completion) -0.043 (-0.026- -0.060) (n=10677) 0.007 (-0.363- 0.378) (n=30) B=0.055±0.164, β=0.003, p=0.736 0.876 
Female participants 
Pairs Matching Test (total number of errors) -0.008 (-0.017- 0.000) (n=54232) 0.074 (-0.061- 0.209) (n=231) B=0.084±0.066, β=0.005, p=0.206 0.288 
Reaction Time Test 0.102 (0.095- 0.110) (n=53772) 0.128 (0.003- 0.252) (n=229) B=0.030±0.060, β=0.002, p=0.620 0.620 
Fluid Intelligence Test (total number of correct answers) 0.046 (0.031- 0.061) (n=16651) -0.030(-0.289- 0.230) (n=67) 
B=-0.076±0.119, β=-0.005, 
p=0.526 
0.614 
Digit Span Test (maximum number of digits remembered) -0.034 (-0.060- -0.008) (n=5404) 0.338 (-0.112- 0.789) (n=18) B=0.372±0.226, β=0.022, p=0.100 0.175 
Symbol Digit Substitution Test (number of correct 
substitutions) 
-0.026 (-0.040- -0.011) (n=15156) -0.277 (-0.504- -0.050) (n=71) 
B=-0.254±0.108, β=-0.019, 
p=0.019 
0.133 
Trail Making Test A (Time to completion) 0.101 (0.084- 0.117) (n=13173) 0.303 90.072- 0.535) (n=64) B=0.203±0.120, β=0.015, p=0.090 0.175 
Trail Making Test B (Time to completion) 0.078 (0.063- 0.094) (n=13200) 0.271 (0.051-0.490) (n=64) B=0.193±0.114, β=0.015, p=0.091 0.175 
Table 4. Volumes of eight subcortical brain regions (right and left hemisphere) in male and female 
duplication carriers and sex-matched controls 
 
Subcortical region  Control group (cm3) Duplication group 
(cm3) 
Statistical analysis Benjamini-Hochberg 
corrected P-value 
Male participants 
Left hemisphere 
Lateral ventricle 13.86 (13.72-14.00) 
(n=8268) 
17.11 (13.78-20.45) 
(n=20) 
B=4.58±2.20, β=0.036, 
p=0.038 
0.56 
Thalamus 7.98 (7.96- 8.01) (n= 
8536) 
7.38 (6.81-7.94) (n=20) B=-0.45±0.36, β=-0.020, 
p=0.202 
0.85 
Caudate 3.58 (3.57-3.59) 
(n=8508) 
3.51 (3.36-3.66) (n=20) B=-0.077±0.16, β=-0.008, 
p=0.629 
0.98 
Putamen 5.27 (5.25-5.28) 
(n=8550) 
5.38 (5.13-5.63) (n=20) B=0.011±0.27, β=0.001, 
p=0.968 
0.98 
Pallidum 1.37 (1.36-1.37) 
(n=8544) 
1.32 (1.30-1.42) (n=20) B=0.028±0.097, β=0.006, 
p=0.772 
0.98 
Hippocampus 4.31 (4.30-4.32) 
(n=8539) 
4.25 (4.03-4.46) (n=20) B=-0.015±0.17, β=-0.002, 
p=0.929 
0.98 
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Amygdala 1.63 (1.63-1.64) 
(n=8531) 
1.62 (1.52-1.72) (n=19) B=-0.073±0.086, β=-0.015, 
p=0.398 
0.98 
Nucleus accumbens 5.28 (5.26-5.31) 
(n=8547) 
5.54 (4.86-6.22) (n=20) B=0.011±0.045, β=0.004, 
p=0.806 
0.98 
Right Hemisphere 
Lateral ventricle 12.88 (12.75-13.01) 
(n=8279) 
14.93 (12.12-17.67) 
(n=20) 
B=2.55±2.05, β=0.021, 
p=0.213 
0.85 
Thalamus 6.93 (6.92-6.95) 
(n=8518) 
6.71 (6.38-7.04) (n=20) B=-0.0065±0.23, β=0.000, 
p=0.977 
0.98 
Caudate 3.75 (3.74-3.76) 
(n=8512) 
3.74 (3.56-3.92) (n=20) B=-0.075±0.17, β=-0.008, 
p=0.651 
0.98 
Putamen 5.05 (5.04-5.06) 
(n=8540) 
5.14 (4.89-5.40) (n=20) B=-0.010±0.22, β=-0.001, 
p=0.963 
0.98 
Pallidum 1.58 (1.58-1.59) 
(n=8517) 
1.62 (1.55-1.70) (n=20) B=0.054±0.076, β=0.013, 
p=0.480 
0.98 
Hippocampus 4.46 (4.45-4.47) 
(n=8535) 
4.37 (4.14-4.56) (n=20) B=0.029±0.17, β=0.003, 
p=0.863 
0.98 
Amygdala 1.70 (1.70-1.71) 
(n=8538) 
1.68 (1.55-1.81) (n=19) B=-0.016±0.087, β=-0.003, 
p=0.858 
0.98 
Nucleus accumbens 5.68 (5.66-5.70) 
(n=8546) 
6.06 (5.60-6.52) (n=20) B=0.073±0.040, β=0.033, 
p=0.070 
0.56 
Female participants 
Left hemisphere 
Lateral ventricle 10.18 (10.07-10.28) 
(n=9364) 
10.53 (8.88-12.18) 
(n=35) 
B=-0.31±1.16, β=-0.004, 
p=0.791 
0.99 
Thalamus 7.22 (7.20-7.24) 
(n=9422) 
6.75 (6.45-7.04) (n=36) B=-0.28±1.91, β=-0.022, 
p=0.141 
0.56 
Caudate 3.31 (3.30-3.32) 
(n=9406) 
3.31 (3.20-3.42) (n=36) B=0.0012±0.091, β=0.000, 
p=0.989 
0.99 
Putamen 4.85 (4.84-4.86) 
(n=9420) 
4.96 (4.74-5.16) (n=36) B=0.31±0.14, β=0.037, 
p=0.033 
0.53 
Pallidum 1.24(1.23-1.24) 
(n=9419) 
1.26 (1.20-1.33) (n=36) B=0.092±0.056, β=0.030, 
p=0.097 
0.56 
Hippocampus 4.08 (4.07-4.09) 
(n=9409) 
3.94 (3.76-4.12) (n=36) B=-0.056±0.089, β=-0.010, 
p=0.534 
0.85 
Amygdala 1.48 (1.48-1.49) 
(n=9405) 
1.47 (1.39-1.55) (n=36) B=0.043±0.048, β=0.015, 
p=0.367 
0.73 
Nucleus accumbens 4.96 (4.94-4.98) 
(n=9419) 
4.88 (4.57-5.20) (n=36) B=0.023±0.025, β=0.016, 
p=0.353 
0.73 
Right Hemisphere 
Lateral ventricle 9.45 (9.35-9.55) 
(n=9351) 
10.02 (8.60-11.44) 
(n=35) 
B=0.20±1.06, β=0.003, 
p=0.853 
0.99 
Thalamus 6.40 (6.39-6.41) 
(n=9415) 
6.21 (6.01-6.41) (n=36) B=-0.096±0.119, β=-0.012, 
p=0.420 
0.75 
Caudate 3.45 (3.44-3.46) 
(n=9411) 
3.43 (3.31-3.55) (n=36) B=0.016±0.094, β=0.003, 
p=0.862 
0.99 
Putamen 4.63 (4.62-4.65) 
(n=9410) 
4.63 (4.34-4.86) (n=36) B=0.19±0.12, β=0.027, 
p=0.118 
0.56 
Pallidum 1.43 (1.43-1.44) 
(n=9395) 
1.43 (1.39-1.48) (n=36) B=0.019±0.041, β=0.008, 
p=0.642 
0.93 
Hippocampus 4.22 (4.21-4.22) 
(n=9410) 
4.15 (4.00-4.32) (n=36) B=-0.097±0.091, β=-0.017, 
p=0.285 
0.73 
Amygdala 1.53 (1.52-1.53) 
(n=9415) 
1.50 (1.43-1.58) (n=36) B=0.004±0.047, β=0.001, 
p=0.938 
0.99 
Nucleus accumbens 5.22 (5.20-5.24) 
(n=9421) 
5.21 (4.88-5.54) (n=36) B=0.021±0.023, β=0.016, 
p=0.361 
0.73 
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Abbreviations 
ADHD  Attention Deficit Hyperactivity Disorder 
CI  Confidence interval 
CNV  Copy Number Variant(s) 
DHEAS Dehydroepiandrosterone sulfate 
GORD  Gastro-oesophageal reflux disease  
ICD-10 International Statistical Classification of Diseases and Related Health Problems Version 10  
OR  Odds Ratio 
Mb  Megabase 
MHQ  Mental Health Questionnaire 
QC  Quality Control 
STS  Steroid sulfatase 
UK  United Kingdom 
XLI  X-linked ichthyosis 
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